Our incomplete understanding of the causes and pathways involved in the onset and
progression of multiple sclerosis (MS) limits our ability to effectively treat this complex …

Importance Multiple sclerosis (MS) is an autoimmune-mediated neurodegenerative disease
of the central nervous system characterized by inflammatory demyelination with axonal …

Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …

Importance To our knowledge, the Oral Ponesimod Versus Teriflunomide In Relapsing
Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease …

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that
involves demyelination and axonal degeneration. Although substantial progress has been …

Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …

In contrast to the multiple disease-modifying therapies that are available for relapsing–
remitting multiple sclerosis (MS), the therapeutic options for progressive MS (PMS) are …

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous
system characterized by inflammatory demyelination and axonal/neuronal damage. The …

Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system that
causes demyelination, axonal degeneration and astrogliosis, resulting in progressive …

There are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of
action currently approved by the US Food and Drug Administration for the treatment of …